NVLN Logo.jpg
Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
June 12, 2017 08:30 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., June 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of...
NVLN Logo.jpg
Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
May 05, 2017 09:00 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
NVLN Logo.jpg
Novelion Therapeutics’ Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
March 30, 2017 16:15 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety
June 16, 2015 16:10 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...